Characteristics of 11 Metastatic NETs Treated with 131I-MIBG Radiotherapy
| Treatment | 131I-MIBG dose (MBq) | ||||||
|---|---|---|---|---|---|---|---|
| Patient no. | Age (y) | Sex | Type of disease | Reason | n | Total | Mean |
| 1 | 64 | F | Pheochromocytoma | New metastasis, multiple lesions, high CA | 3 | 16,650 | 308.21 |
| 2 | 45 | F | Paraganglioma | New metastasis, multiple lesions | 3 | 16,650 | 326.34 |
| 3 | 45 | M | Pheochromocytoma | New metastasis, multiple lesions | 3 | 16,650 | 180.93 |
| 4 | 34 | F | Pheochromocytoma | New metastasis, multiple lesions | 2 | 11,100 | 182.41 |
| 5 | 62 | F | Pheochromocytoma | New metastasis, multiple lesions, high CA | 3 | 16,650 | 358.16 |
| 6 | 65 | F | Paraganglioma | New metastasis, multiple lesions, high CA | 3 | 16,650 | 323.38 |
| 7 | 67 | F | Pheochromocytoma | New metastasis, multiple lesions, high CA | 2 | 11,100 | 216.08 |
| 8 | 36 | F | Pheochromocytoma | New metastasis, multiple lesions | 3 | 16,650 | 391.83 |
| 9 | 49 | M | Thyroid medullary cancer | New metastasis, multiple lesions | 3 | 16,650 | 256.04 |
| 10 | 52 | F | Pheochromocytoma | CVD resistance | 3 | 16,650 | 263.07 |
| 11 | 22 | F | Pheochromocytoma | New metastasis (recurrence), high CA | 3 | 16,650 | 339.66 |
| Mean ± SD | 49 ± 15 | 15,640.9 ± 2,245.1 | 286.01 ± 71.33 | ||||
↵CA = catecholamine; CVD = cyclophosphamide, vincristine, and dacarbazine; new metastasis = newly diagnosed metastasis.